Please assess the completion status of the following clinical trial:

Trial Title: EverolimuS-ElUtinG BioresorbAble VasculaR Scaffolds vErsus EVerolimus-Eluting Stents in Patients With Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Clinical inclusion criteria:~* Age ≥18 years~* DM type I or II based on the definitions of the American Diabetes Association~* Angiographically proven CAD~* Angina pectoris, equivalent symptoms, and/or positive stress test, and/or instantaneous flow reserve ≤0.86, and/or fractional flow reserve ≤0.80~* Negative pregnancy test in women with childbearing potential~Angiographic inclusion criteria:~* De-novo lesion in at least one native coronary artery~* Luminal diameter reduction 50-99% assessed by visual estimation~* Target reference vessel diameter 2.5 - 4.0 mm~Clinical exclusion criteria:~* Limited long-term prognosis with a life-expectancy \<12 months~* Contraindications to antiplatelet therapy~* Known allergy against cobalt chrome, everolimus, or polylactic acid~Angiographic exclusion criteria:~* Target lesion located in the left main trunk~* Severe calcification of the target lesion as determined by angiography~* In-stent restenosis~* Bifurcation lesion with planned two-stent strategy~* Chronic total occlusion~* Indication for CABG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Absorb GT1 (Type: EXPERIMENTAL): Bioresorbable everolimus-eluting scaffolds
- Promus (Type: ACTIVE_COMPARATOR): Everolimus-eluting stents

Based on this trial design, predict the completion outcome and termination type (if applicable).